Deepak Gondaliya
Corporate Officer/Principal presso Emcure Pharmaceuticals Ltd.
Profilo
Deepak Gondaliya is currently working as the President-Technical Operations at Emcure Pharmaceuticals Ltd.
He previously worked as the Deputy General Manager-Research & Development at Sun Pharmaceutical Industries Ltd.
Dr. Gondaliya holds a doctorate degree from Hemchandracharya North Gujarat University.
Posizioni attive di Deepak Gondaliya
| Società | Posizione | Inizio |
|---|---|---|
Emcure Pharmaceuticals Ltd.
 Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Corporate Officer/Principal | 01/07/2013 |
Precedenti posizioni note di Deepak Gondaliya
| Società | Posizione | Fine |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Corporate Officer/Principal | - |
Formazione di Deepak Gondaliya
| Hemchandracharya North Gujarat University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Health Technology |
- Borsa valori
- Insiders
- Deepak Gondaliya
